L
Luyu Yang
Researcher at Wuhan University
Publications - 3
Citations - 332
Luyu Yang is an academic researcher from Wuhan University. The author has contributed to research in topics: Interquartile range & Intensive care. The author has an hindex of 3, co-authored 3 publications receiving 210 citations.
Papers
More filters
Journal ArticleDOI
Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China.
Jiqian Xu,Xiaobo Yang,Luyu Yang,Xiaojing Zou,Yaxin Wang,Yongran Wu,Ting Zhou,Yin Yuan,Hong Qi,Shouzhi Fu,Hong Liu,Jia'an Xia,Zhengqin Xu,Yuan Yu,Ruiting Li,Yaqi Ouyang,Rui Wang,Lehao Ren,Yingying Hu,Dan Xu,Xin Zhao,Shiying Yuan,Dingyu Zhang,You Shang +23 more
TL;DR: The duration of the negative conversion of SARS-CoV-2 RNA and its association with the severity of critically ill patients with COVID-19 should be seriously considered and further studied.
Journal ArticleDOI
Patients with COVID-19 in 19 ICUs in Wuhan, China: a cross-sectional study.
Yuan Yu,Dan Xu,Shouzhi Fu,Jun Zhang,Xiaobo Yang,Liang Xu,Jiqian Xu,Yongran Wu,Chaolin Huang,Yaqi Ouyang,Luyu Yang,Minghao Fang,Hongwen Xiao,Jing Ma,Wei Zhu,Song Hu,Quan Hu,Daoyin Ding,Ming Hu,Guochao Zhu,Weijiang Xu,Jun Guo,Jinglong Xu,Haitao Yuan,Bin Zhang,Zhui Yu,Dechang Chen,Shiying Yuan,You Shang +28 more
TL;DR: Critically ill patients with COVID-19 are associated with a higher risk of severe complications and need to receive an intensive level of treatments, and these patients are investigated in a multicenter prospective observational study.
Journal ArticleDOI
A Novel Risk-Stratification Models of the High-Flow Nasal Cannula Therapy in COVID-19 Patients With Hypoxemic Respiratory Failure
Jiqian Xu,Xiaobo Yang,Chaolin Huang,Xiaojing Zou,Ting Zhou,Shangwen Pan,Luyu Yang,Yongran Wu,Yaqi Ouyang,Yaxin Wang,Dan Xu,Xin Zhao,Huaqing Shu,Yongxiang Jiang,Wei Xiong,Lehao Ren,Hong Liu,Yin Yuan,Hong Qi,Shouzhi Fu,Dechang Chen,Dingyu Zhang,Shiying Yuan,You Shang +23 more
TL;DR: Aged patients with lower ROX index, thrombocytopenia, and elevated IL-6 values are at increased risk of HFNC failure, and early stratified COVID-19 patients with HFNC therapy into relevant risk categories are stratified.